Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

NovoCure Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

NovoCure şirketinin toplam hissedar öz sermayesi $361.8M ve toplam borcu $653.5M olup, bu da borç-öz sermaye oranını 180.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $1.2B ve $850.4M dir.

Anahtar bilgiler

180.6%

Borç/özkaynak oranı

US$653.47m

Borç

Faiz karşılama oranı	n/a
Nakit	US$951.19m
Eşitlik	US$361.75m
Toplam yükümlülükler	US$850.42m
Toplam varlıklar	US$1.21b

Son finansal sağlık güncellemeleri

Recent updates

Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects

Sep 12

NovoCure Limited: A Post Q2 Analysis

Jul 26

NovoCure Limited Q1 Earnings: Core Business Accelerating

May 03

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

Apr 08

NovoCure: Sell The METIS-Inspired Rally

Mar 28

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Mar 03

NovoCure: Stay Cautious Amid Positive Signs

Jan 19

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Nov 16

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Aug 13

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

May 15

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Apr 24

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Feb 10

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Jan 16

NovoCure: See Past Market Myopia And Buy The Dip

Sep 27

Novocure creates new CNS focused franchise to renew growth in brain cancer business

Sep 21

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Sep 09

NovoCure: Does The Reward Outweigh The Risk? I Believe So

Sep 09

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NVCR 'nin kısa vadeli varlıkları ( $1.1B ) kısa vadeli yükümlülüklerini ( $169.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: NVCR şirketinin kısa vadeli varlıkları ( $1.1B ) uzun vadeli yükümlülüklerini ( $681.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NVCR şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: NVCR şirketinin borç/öz sermaye oranı son 5 yılda 94% seviyesinden 180.6% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NVCR şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: NVCR tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

NovoCure Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Recent updates

NovoCure Limited to Report Q3, 2024 Results on Oct 30, 2024

Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects

Novocure Announces CEO Changes, Effective January 1, 2025

Consensus estimates of losses per share improve by 15%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

NovoCure Limited: A Post Q2 Analysis

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Chief Operating Officer exercised options to buy US$2.7m worth of stock.

Now 22% undervalued

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

Now 22% undervalued

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Q1 Earnings: Core Business Accelerating

NovoCure Limited announced that it expects to receive $400 million in funding

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

New minor risk - Insider selling

New minor risk - Shareholder dilution

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

NovoCure: Sell The METIS-Inspired Rally

Price target increased by 8.8% to US$27.20

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Full year 2023 earnings: EPS exceeds analyst expectations

NovoCure: Stay Cautious Amid Positive Signs

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Chief Financial Officer exercised options to buy US$231k worth of stock.

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.25 loss in 3Q 2022)

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Price target decreased by 42% to US$35.17

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Price target decreased by 9.4% to US$60.33

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Price target decreased by 16% to US$64.17

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

Consensus EPS estimates fall by 31%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 20% to US$82.00

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Consensus EPS estimates fall by 12%

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer recently sold US$165k worth of stock

Consensus EPS estimates fall by 31%

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Novocure Announces Executive Changes

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

President notifies of intention to sell stock

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Price target increased to US$98.86

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting